For the hiemophiliac, cryoprecipitate has made possible prompt, quick and, above all, adequate treatment for any form of heemorrhage. Unfortunately, it is useless for patients with Christmas disease.
In 1965-6 a joint trial of the preparation and use of cryoprecipitate was carried out between the Hemophilia Centres of the Hospital for Sick Children, Great Ormond Street, and the Royal Free Hospital, in collaboration with the North London Blood Transfusion Centre (Bennett et al. 1967 , Brown et al. 1967 . During the first nine months of this trial the precipitate was made at both hospital Haemophilia Centres. Once we were convinced that the method worked the Trans-fusion Centre took over the production. They now supply all the six Hemophilia Centres in the area; their production is of the order of 400 bags of cryoprecipitate a week. Each bag contains approximately 10-15 ml of concentrate with a factor-VIII-assay level of 800-1,500 % (80-225 units factor VIII per bag).
The technique of preparation depends on the fact that, when fresh-frozen plasma is thawed in the cold, a precipitate containing factor VIII and fibrinogen separates out. By a series of manipulations, in a closed plastic bag system, it is possible to remove the factor VIII from fresh blood without damaging the other blood components.
The method used, which is slightly modified from Pool's original technique, is as follows:
Five hundred millilitres of blood is taken from a donor into a Fenwal JD2 double plastic bag, placed in a container at 4°C and processed within two hours of collection. The double bag is spun at 4,600 rev/min for fifteen minutes at 4°C in the superspeed blood bag head of a MSE Mistral centrifuge, after which the plasma is transferred into the second bag and a temporary seal placed on the connecting tube. The plasma is then rapidly frozen in a carbon dioxide alcohol mixture, after which it is thawed in a bucket of water at 8°C. At this temperature the cryoprecipitate, containing factor VIII and some fibrinogen, remains insoluble while the rest of the plasma becomes liquid. The bags are then re-spun and the cryoprecipitate forms an adherent sediment at the bottom of the plasma bag. Next the temporary seal between the two bags is removed and the main volume of supernatant plasma is allowed to run back into the red cell bag, leaving behind about 10 ml with the cryoprecipitate. (Alternatively, the supernatant can be transferred into a separate container.) The connecting tube is sealed and severed and the cryoprecipitate, in a total volume of 10-15 ml of supernatant, is stored at -30°C.
At the time of use the correct number of bags is removed from the deep freeze and thawed at 37°C. The cryoprecipitate is pooled into one or two large syringes and injected into the patient.
The factor VIII level to be aimed at in the patient increases with the risk involved with a particular hemorrhage. In the case of a haemarthrosis a single injection, aiming at a factor VIII level of 20% and given on an outpatient basis, is often sufficient. After a severe joint or Certain operations, e.g. himorrhoidectomy or excision of a pseudo-tumour, undoubtedly require greater cover than other less hemorrhagic operations and it would be unwise to lay down a hard and fast dosage scheme. If the initial priming dose is one that aims to raise the factor VIII level to 100%, half of that number of bags per day, and 100 X I hatmophilla. The number ofbags ofcryoprecipitate is indicated above the coinm9s. One unit factor VII11 mlplasma,factor VIII 100% muscle bleed (e.g. a hemarthrosis of the knee, which may have required aspiration, or a hemorrhage into the ileo-psoas muscle) rehabilitation can often be hastened by giving cryoprecipitate during mobilization.
Deep muscle hemorrhage is particularly liable to result in crippling deformities so, for this type of bleed, one aims a little higher -35-40%, for example. We aim at still higher levels for an acute abdomen or severe headache, when maintenance of the factor VIII level above 30-40 % becomes as important as it is with dental extractions and other surgical procedures.
The following formula (Brown et al. 1967 ) is used to estimate the dose of cryoprecipitate required:
given in two divided doses, should keep the patient's level of factor VIII above 30% during the post-operative period.
Fig 1 illustrates the cryoprecipitate cover given to a severely affected hemophiliac, aged 61 years and weighing 70 kg, whose inguinal hernia was repaired in June 1967. Thirty bags of cryoprecipitate, given pre-operatively, raised the patient's factor VIII level from 0 to 100%. Thereafter, an average of 16 bags a day, given in two divided doses, proved adequate to maintain the factor VIII level at over 30% for most of the time. The number of bags given for each dose is shown above the columns which represent the doses in units of factor VIII. From these it can be seen that there is considerable variation in activity between bags. While, for the most part, every-Section ofMedicine thing went quite regularly, the 9 bags given on the eleventh day turned out to be a particularly low dose and, in consequence, the response was similarly poor. This illustrates the importance of doing assays. As the poor response was discovered at once a second dose could be given immediately. Admittedly, on the eleventh day it was not so importantbut this could have happened on the second or third day when, if not found at once, it would have mattered very much. One must not leave it all to chance! Pre-and post-infusion plasma fibrinogen levels were estimated daily, by the Buiret method. The highest level, recorded on ninth day, was 820 mg/100 ml plasma. There were no post-operative complications and the patient made an uninterrupted recovery.
The total number of bags used to cover this operation was 263. The cost of a bag of cryoprecipitate is estimated at 35s (T E Cleghorn, personal communication), giving a cost of £460 for the production of therapeutic material to cover this operation.
The factors which most affect the final activity of a dose are the activity of the starting material, the speed of preparation and the volume of supernatant left behind with the cryoprecipitate.
Since it is not possible to check the activity of cryoprecipitate at the time of preparation, this must be done regularly on use. A further reason for these checks is that some patients tend to need much higher doses than others, even though they have not developed an inhibitor to factor VIII. If an inhibitor does develop it is most likely to be first detected on the post-infusion assay results, which will show a lack of response to treatment. Once an inhibitor has developed, treatment with any plasma preparation is withheld for all but a major haemorrhage, when massive doses of concentrate must be given.
In general, our aim is to assay the patient's dose response -that is the pre-and post-infusion samples and the dose administeredthe first time patients are infused and then at approximately two to three monthly intervals when they are on fairly regular treatment. We also always assay for the more serious types of hcemorrhage, namely groin hmmorrhage, acute abdomen, severe headache, joint aspiration, dental extraction and other operative procedures and if there is, with any type of hemorrhage, a failure of clinical response. A pooled dose of cryoprecipitate is tested once a week and as part of every dose-response. This need for frequent and prompt assaying of both the patient's blood and the therapeutic materials used is, perhaps, the most important reason for all patients with coagulation disorders to be registered at specialist hemophilia centres.
It is not possible to make a comparison between cryoprecipitate and freeze-dried human antihemophilic factor for our own supplies of the latter material are virtually non-existent. In comparison with fresh-frozen plasma, however, cryoprecipitate is much more reliable; the small volume puts much less strain on the circulation, especially where high factor VIII levels are required; it is quicker for all concerned. Being able to give a small volume quickly, through a syringe, is invaluable when treating children. When given whole plasma more than half our patients had allergic reactions; we have had only one instance of an allergic reaction when using cryoprecipitate and this responded to the usual measures.
Since any level of factor VIII can be reached, cryoprecipitate is suitable as cover for major surgery as well as for the treatment of other types of himorrhage. As we now have an adequate supply we can give regular prophylactic treatment when it is indicated. The patients who receive this therapy from us come up to be given their injections but Professor Prankerd has a patient who gives his own injections (Bellingham et al. 1967 (Fig 3) while the supernatant plasma can be used for patients with Christmas disease and PTA deficiency. As it is not concentrated the volume given must be the same as that for whole plasma infusions, i.e. 15-20 ml/kg body weight. In Christmas disease, particularly, both supernatant and fresh-frozen plasma are suitable only for the treatment of relatively minor bleeds as they are unlikely to raise the level of factor IX above 15 %. If the supernatant plasma is used the red cells will be issued as packed cells. If, as in the case of our own preparation, most of the supernatant is returned to the red cells these are issued as reconstituted blood.
Although the method for producing cryoprecipitate is simple enough for it to be made in hospital laboratories it is, obviously, more economical if it is made at blood transfusion centres. Since the first stage of preparing cryoprecipitate involves making fresh-frozen plasma, there is no reason why the development of decentralized production of factor-VIII-cryoprecipitate by blood transfusion centres should interfere with any major programmes of blood fractionation.
Provided that both programmes are developed together, none of the effort, time and money expended on the production of cryoprecipitate will be wastedand patients will get better treatment very much sooner than if we await the products of a new fractionation plant.
Meanwhile, let us hope that the interest already shown by a number of blood transfusion centres in the preparation of cryoprecipitate will spread throughout the country so that adequate supplies of this form of factor VIII concentrate will soon become available to all haemophilia centres. The simple technique developed by Dr Judith Pool for the production of a concentrate of factor VIII, the so-called cryoglobulin methodhas been described in detail by Dr Dormandy. The purpose of the present paper is to show why the more sophisticated methods of plasma fractionation are still necessary. The advantages of cryoprecipitate are its availability and usually high concentration. It is often useful to be able to administer a dose by syringe although one should keep in mind that reactions in the patient might be more difficult to control if a dose is administered rapidly and that the more concentrated the material the more one wastes in unavoidable handling losses. But the option of choosing to administer by syringe should be available to the clinician. This does not necessarily mean that the preparation of cryoprecipitate in a multiplicity of centres is the best long term national policy.
If, as I believe, a centralized fractionation procedure could supply a factor VIII concentrate with all the desirable criteria, what should these be? First one should be able to rely on its potency. This implies it should have been previously assayed by a reproducible method and should be stable on storage. Its potency should be high enough to permit injection by syringe if clinically desirable. It should be readily and completely soluble and conform to accepted tests for sterility and general toxicity and as far as possible be free from side-effects.
Economy in the use of blood demands that as much as possible of the components should be utilized. If a patient needs only red cells, we usually supply him with plasma as well as red cells and may be deluding ourselves if we regard that plasma as 'used'. There is no doubt that concentrated red cells could be given to many more patients than at present, and the plasma diverted to other clinical uses.
If sufficient plant and staff were available, the supernatant from cryoprecipitate could be fractionated in a similar manner to whole plasma, providing all the usual products with the possible exception of fibrinogen. It would also permit the
